1 |
Almazroo OA, Miah MK, Venkataramanan R. Drug Metabolism in the Liver. Clin Liver Dis 2017;21:1-20.
DOI
|
2 |
Pariente A, Etcharry F, Cales V, Laborde Y, Ferrari S, Biour M. Imatinib mesylate-induced acute hepatitis in a patient treated for gastrointestinal stromal tumour. Eur J Gastroenterol Hepatol 2006;18:785-7.
DOI
|
3 |
Tonyali O, Coskun U, Yildiz R, Karakan T, Demirci U, Akyurek N, et al. Imatinib mesylate-induced acute liver failure in a patient with gastrointestinal stromal tumors. Med Oncol 2010;27:768-73.
DOI
|
4 |
Seidel C, Fenner M, Langer F, Bantel H, Ganser A, Grunwald V. Imatinib-induced liver cirrhosis in a patient with advanced gastrointestinal stroma tumor (GIST). BMC Cancer 2012;12:186.
DOI
|
5 |
Yachoui R. Early onset imatinib mesylate-induced hepatotoxicity in a patient with gastrointestinal stromal tumors. Am J Ther 2014;21:e148-50.
DOI
|
6 |
Ferrero D, Pogliani EM, Rege-Cambrin G, Fava C, Mattioli G, Dellacasa C, et al. Corticosteroids can reverse severe imatinib-induced hepatotoxicity. Haematologica 2006;91(6 Suppl): ECR27.
|
7 |
Al Sobhi E, Zahrani Z, Zevallos E, Zuraiki A. Imatinib-induced immune hepatitis: case report and literature review. Hematology 2007;12:49-53.
DOI
|
8 |
Guilhot F. Indications for imatinib mesylate therapy and clinical management. Oncologist 2004;9:271-81.
DOI
|
9 |
Sharma A, Houshyar R, Bhosale P, Choi JI, Gulati R, Lall C. Chemotherapy induced liver abnormalities: an imaging perspective. Clin Mol Hepatol 2014;20:317-26.
DOI
|
10 |
Joensuu H, Trent JC, Reichardt P. Practical management of tyrosine kinase inhibitor-associated side effects in GIST. Cancer Treat Rev 2011;37:75-88.
DOI
|
11 |
Doring B, Petzinger E. Phase 0 and phase III transport in various organs: combined concept of phases in xenobiotic transport and metabolism. Drug Metab Rev 2014;46:261-82.
DOI
|
12 |
Willson TM, Kliewer SA. PXR, CAR and drug metabolism. Nat Rev Drug Discov 2002;1:259-66.
DOI
|
13 |
Hunt CM, Papay JI, Stanulovic V, Regev A. Drug rechallenge following drug-induced liver injury. Hepatology 2017;66:646-54.
DOI
|
14 |
Saif MW, Smith MH, Maloney A, Diasio RB. Imatinib-induced hyperbilirubinemia with UGT1A1 (*28) promoter polymorphism: first case series in patients with gastrointestinal stromal tumor. Ann Gastroenterol 2016;29:551-6.
|